HLA-B*58:01 identifies those at risk for severe cutaneous adverse skin reaction to allopurinol. 

Learning Objectives

  • Learn about new HLA-B*58:01 genotyping that identifies patients at risk for severe cutaneous adverse skin reaction to allopurinol.
  • Recognize that allopurinol hypersensitivity is associated with a marked morbidity and mortality rate of up to 20%-25%.
  • Educate on the guidelines:  The American College of Rheumatology and The Clinical Pharmacogenomics Implementation Consortium and recommend testing prior to treatment with allopurinol.
  • Recognize patients at higher risk. Highest allele frequency occurs in Koreans (12%), Thai (9%), Han Chinese (7%), and African Americans (4%). But Pacific Islander (2%), Hispanic (1%), Native American (1%),  Caucasians (1%), and Japanese (1%) are also at risk. 
  • Note that cost of HLA-B*58:01 testing is far less than a hospital stay for your patient. 

Faculty Information

Robert A. Baldor, MD, FAAFP

Senior Vice Chair, Family Medicine & Community Health- UMass Memorial Medical Center
Professor, University of Massachusetts Medical School
UMass Memorial Medical Center 


Quest Diagnostics